RA Cap­i­tal aims to take pre­clin­i­cal biotech to Nas­daq as Tyra files S-1 dur­ing sum­mer lull

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The sum­mer has brought a rel­a­tive breather to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER